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Background and Purpose Despite the widespread adoption of mechanical thrombectomy (MT) for 
the treatment of large vessel occlusion stroke (LVOS) in the anterior circulation, the optimal 
strategy for the treatment tandem occlusion related to cervical internal carotid artery (ICA) 
dissection is still debated. This individual patient pooled analysis investigated the safety and 
efficacy of prior intravenous thrombolysis (IVT) in anterior circulation tandem occlusion related to 
cervical ICA dissection treated with MT.
Methods We performed a retrospective analysis of two merged prospective multicenter 
international real-world observational registries: Endovascular Treatment in Ischemic Stroke (ETIS) 
and Thrombectomy In TANdem occlusions (TITAN) registries. Data from MT performed in the 
treatment of tandem LVOS related to cervical ICA dissection between January 2012 and December 
2019 at 24 comprehensive stroke centers were analyzed. The primary endpoint was a favorable 
outcome defined as 90-day modified Rankin Scale (mRS) score of 0–2.
Results The study included 144 patients with tandem occlusion LVOS due to cervical ICA 
dissection, of whom 94 (65.3%) received IVT before MT. Prior IVT was significantly associated with 
a better clinical outcome considering the mRS shift analysis (common odds ratio, 2.59; 95% 
confidence interval [CI], 1.35 to 4.93; P=0.004 for a 1-point improvement) and excellent outcome 
(90-day mRS 0–1) (adjusted odds ratio [aOR], 4.23; 95% CI, 1.60 to 11.18). IVT was also associated 
with a higher rate of intracranial successful reperfusion (83.0% vs. 64.0%; aOR, 2.70; 95% CI, 1.21 
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Introduction
Since the adoption of mechanical thrombectomy (MT) for the 
treatment of patients with acute large vessel occlusion strokes 
(LVOS),1 the role of prior intravenous thrombolysis (IVT) has 
been debated. Recent publications of the DIRECT-MT, SKIP, 
DEVT, and MR-CLEAN NO-IV trials and ongoing SWIFT-DIRECT 
trial are expected to bring part of the answer.2-5 However, given 
the rarity of tandem occlusions in particular related to cervical 
internal carotid artery (ICA) dissection, these trials might not 
answer the question for this very specific subgroup. A high clot 
burden, the need for antiplatelet therapy if emergency ICA 
stenting is required, along with concerns about intracranial 
bleeding and extension or worsening of the arterial dissection 
are frequently raised arguments for avoiding prior IVT prior to 
MT. The efficacy and safety of IVT on ICA dissection-related 
strokes has been reported for all presentations, but without 
emphasis on tandem LVOS.6,7 Tandem occlusion related to cer-
vical ICA dissection is a singular entity with a specific thera-
peutic strategy regarding endovascular treatment and associ-
ated medical treatment.8-12 This is an important question to 
address given the lack of data and various therapeutic alterna-
tives based on local protocols. Therefore, this study assessed 
the impact of prior IVT on patients treated with MT for tandem 
LVOS related to cervical ICA dissection. 
Methods
Study population
We performed a retrospective analysis of prospectively main-
tained multicenter observational registries. The study popula-
tion was composed of two merged databases: Endovascular 
Treatment in Ischemic Stroke (ETIS; NCT03776877) from May 
2012 to December 2019 and Thrombectomy In TANdem (TITAN) 
lesions from January 2012 to September 2016. ETIS is an ongo-
ing prospective multicentric registry collecting data from con-
secutive patients benefiting from endovascular treatment for 
LVOS at six French comprehensive stroke centers.6 The TITAN 
collaboration pooled individual data from non-randomized 
thrombectomy databases from 18 international centers for all 
consecutive anterior circulation tandem occlusions treated 
with MT.7 Our analysis included patients with anterior circula-
tion tandem occlusions due to cervical ICA dissection treated 
with an endovascular approach. Tandem occlusions were de-
fined as cervical ICA occlusion or high-grade stenosis associat-
ed with a second distinct intracranial occlusion (intracranial 
segment of ICA, M1, or M2 segments of the middle cerebral 
artery [MCA]). ICA dissection diagnosis was based on angio-
graphic features (per-thrombectomy angiographic aspect), im-
aging explorations demonstrating cervical ICA arterial wall he-
matoma, epidemiological data, and exclusion of differential 
stroke etiologies. Patients presenting with simultaneous multi-
ple and confounding potential LVOS etiologies were excluded 
(for example, in case of co-existing atrial fibrillation).
Treatments
The indications for MT were based on the timeframes, imaging 
data, global comorbidities, and standard guidelines, after mul-
tidisciplinary discussion. IVT was performed within 4.5 hours 
after onset according to the international guidelines, using re-
combinant tissue plasminogen activator (alteplase, 0.9 mg/kg) 
in the absence of contraindications. MT was performed de-
pending on the patient’s condition and local protocol. The en-
dovascular strategy was left to the discretion of the interven-
tionist, especially for intracranial MT approach (stent retriever 
alone, contact aspiration, or stent retriever+aspiration combi-
nation), emergency ICA stenting, and perioperative antiplatelet 
therapy. Depending on operator’s choice, peroperative aspirin 
intravenous bolus (250 to 500 mg) was administered. In case 
of cervical stenting, oral antiplatelet therapy was initiated after 
day-1 imaging according to the neurological condition, infarct 
extension, intracranial hemorrhage (ICH) and cervicocerebral 
arteries patency and chosen among the following possibilities: 
dual or simple antiplatelet therapy or none.
Data collection
The data used in this study are available from the correspond-
ing author upon reasonable request. Clinical, imaging, timeline, 
to 6.03) and a lower rate of symptomatic intracranial hemorrhage (4.3% vs. 14.8%; aOR, 0.21; 
95% CI, 0.05 to 0.80).
Conclusions Prior IVT before MT for the treatment of tandem occlusion related to cervical ICA 
dissection was safe and associated with an improved 90-day functional outcome.
Keywords Stroke; Internal carotid artery; Dissection; Reperfusion; Thrombolytic therapy
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and angiographic data were recorded. Trained research nurses 
assessed the modified Rankin Scale (mRS) score at 90 days, 
during face-to-face interviews or via telephone conversations 
with the patients, their relatives or their general practitioners. 
Imaging data were assessed by experienced (>10 years) senior 
investigators in participating centers. Favorable and excellent 
outcomes were respectively defined as a 90-day mRS score 
0–2 and 0–1. Day-1 National Institutes of Health Stroke Scale 
(NIHSS) was recorded. Successful reperfusion was defined as 
modified Thrombolysis In Cerebral Infarction (mTICI) 2b-3. A 
first pass effect was defined as mTICI 2b-3 after one pass. Pro-
cedural complications (dissection, embolism in a new territory 
[ENT], and arterial perforation) and 90-day mortality were re-
corded. ICH was assessed according to the ECASS II classifica-
tion. Symptomatic intracerebral hemorrhage (sICH) was de-
fined as neurological deterioration (NIHSS worsening ≥4 points 
or death) along with ICH. Patency of the cervical carotid artery 
was evaluated on day-1 imaging follow-up (magnetic reso-
nance angiography or computed tomography angiography).
Statistical analysis 
Categorical variables were expressed as frequencies and per-
centages. Quantitative variables were expressed as the 
mean±standard deviation or median (interquartile range) ac-
cording to the normality of distribution which was assessed 
using histograms and the Shapiro-Wilk test. Patients were di-
vided in two groups according to whether IVT was used before 
groin puncture. The patient and treatment characteristics were 
described and compared between the two study groups using 
chi-square test for categorical variables (or using Fisher’s exact 
test when expected cell frequency <5) and using Student's t-
test for quantitative variables (or using Mann-Whitney U test 
for non-normal distribution); magnitudes of the between-
group differences were assessed by calculating the absolute 
standardized differences; an absolute standardized difference 
<20% was interpreted as a small difference.
We compared outcomes in the two study groups before and 
after adjustment on onset to groin puncture, site of occlusion 
and cervical ICA stenting for angiographic outcomes and on 
pre-treatment NIHSS, pre-treatment Alberta Stroke Program 
Early CT Score (ASPECTS) and onset to groin puncture for clini-
cal outcomes. A sensitivity analysis was done by excluding 
from the no-IVT group the patients outside the time window 
for IVT and those with extended infarct core on initial imaging. 
Binary outcomes (favorable and excellent outcomes, 90-day 
all-cause mortality, successful reperfusion, first pass effect, pa-
tency of the extracranial carotid artery, and procedural and 
hemorrhagic complications) were compared using logistic re-
gression models (using penalized approach to account smaller 
number of events for procedural complication, all-cause mor-
tality, parenchymal hematoma and symptomatic intracerebral 
hemorrhage); odds ratios (ORs) were calculated as the effect 
size using patients in the non-IVT group as the reference. The 
overall distribution of mRS and number of passes were com-
pared using an ordinal logistic regression model (shift analysis 
mRS 5 and 6 and number of passes >5 pooled together); the 
common odds ratio (cOR) for a 1-point improvement in mRS 
and number of passes were derived from this model as the ef-
fects size. The groin-puncture-to-successful-reperfusion time 
and 24-hour NIHSS and ASPECTS changes were compared us-
ing a generalized linear regression model; mean between-
group differences (IVT vs. non-IVT groups) were derived from 
this model as the effect size. The normality of model residuals 
was established after log-transformation of the groin punc-
ture-to-successful-reperfusion time. Multivariate analyses 
were performed after handling missing values for confounding 
factors and outcomes using multiple imputation. The imputa-
tion procedure was performed with a regression-switching ap-
proach (chained equations with n=10) under the missing at 
random assumption using all baseline characteristics and study 
outcomes with a predictive mean matching method for con-
tinuous variables and logistic regression models (binary, ordi-
nal, or multinomial) for categorical variables. Estimates ob-
tained with the different imputed datasets were combined us-
ing Rubin’s rules.
Statistical testing was done at the two-tailed α level of 0.05. 
The data were analyzed using SAS release 9.4 (SAS Institute, 
Cary, NC, USA).
Ethics statement
Ethics approval was obtained from the local institutional re-
view board. Informed consent was obtained for all the patients.
Results
Of the 770 LVOS patients with tandem lesions enrolled in the 
TITAN (n=369) and ETIS (n=401) registries, this study included 
144 patients with cervical ICA dissection, of whom 94 (65.3%) 
underwent IVT (Figure 1). Table 1 summarizes the main patient 
and treatment characteristics according to IVT. The two groups 
were well balanced, except for hypercholesterolemia, current 
smoking, and site of occlusion (M2-MCA occlusion less fre-
quent in IVT group). The reasons for no-IVT were outside the 
time window (n=15), unknown onset (n=7), extended infarc-
tion (n=8), interdisciplinary choice (n=12), prior double anti-
platelet therapy (n=1), international normalized ratio >1.7 
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(n=1), recent abdominal surgery (n=1), and missing data (n=5).
As shown in Table 2, a higher rate of favorable outcome 
(pre-specified as primary outcome) was observed in the IVT 
group (62.6% vs. 47.8%) although the difference did not reach 
statistical significance (OR, 1.83; 95% confidence interval [CI], 
0.89 to 3.75). When the overall degree of disability was ana-
lyzed, the difference in favor of the IVT group reached signifi-
cance (Figure 2), and also when an excellent outcome was 
considered (OR, 4.36; 95% CI, 1.67 to 11.34). Similar results 
were found after pre-specified adjustment for pre-treatment 
NIHSS, ASPECTS, and onset to groin puncture time, with an 
adjusted odds ratio (aOR) for the IVT group of 2.44 (95% CI, 
1.28 to 4.61) for a 1-point improvement in the mRS score and 
4.23 (95% CI, 1.60 to 11.18) for an excellent outcome. The rate 
of successful reperfusion was higher in the IVT group (83.0% 
vs. 64.0%; aOR, 2.63; 95% CI, 1.12 to 6.15). Regarding other 
clinical efficacy outcomes, patients in the IVT group had a sig-
nificantly greater reduction in day-1 NIHSS (adjusted mean 
difference, 3.6 points; 95% CI, 0.6 to 4.6) and a lower worsen-
ing in day-1 ASPECTS (adjusted mean difference, –0.8 points; 
95% CI, –1.6 to 0.03). sICH and any ICH were also significantly 
less frequent in IVT group, with a respective aOR of 0.21 (95% 
CI, 0.05 to 0.80) and 0.41 (95% CI, 0.17 to 0.96). Similar non-
significant differences in all-cause mortality and parenchymal 
hematoma rates were found. Peroperative complication rates 
were comparable between groups (18.0% vs. 9.6%; aOR, 0.46; 
95% CI, 0.15 to 1.33). Detailed complications were as follow: 
nine cases in the no-IVT group (eight ENT and one perforation) 
and nine in the IVT group (three ENT, five perforations, and one 
extension and worsening of ICA dissection).
The results of sensitivity analysis, after exclusion from the 
no-IVT group of 15 patients outside the IVT time window and 
eight with large infarction on initial imaging, are presented in 
Supplementary Table 1. A significantly higher rate of successful 
reperfusion was observed in the IVT group (83.0% vs. 63.0%; 
unadjusted OR, 2.87; 95% CI, 1.11 to 7.41). Notably, ICH, pa-
renchymal hematoma, and sICH rates were comparable be-
tween groups with respective unadjusted ORs of 0.86 (95% CI, 
0.31 to 2.36), 0.50 (95% CI, 0.12 to 2.02), and 0.78 (95% CI, 
0.11 to 5.40).
Discussion
Two important findings emerged from this individual patient 
pooled study. First, bridging therapy resulted in a better func-
tional outcome compared to MT alone. Second, the use of IVT 
before MT was associated with lower odds of ICH and sICH.
The recent publication of the DIRECT-MT, SKIP, and DEVT trials 
and the presentation of MR-CLEAN NO-IV trial results revealed 
evidence in favor of the non-inferiority of MT alone versus bridg-
ing therapy in LVOS.2-5 The benefit of systematic use of IVT prior 
to MT remains debated and more evidence is needed before cur-
rent guidelines are modified.8 In addition, rare and specific oc-
clusion subtypes, such as tandem occlusions, are either under-
represented or often excluded2 in such trials, emphasizing the 
importance of results from large retrospective cohorts.
In our population, successful reperfusion was more frequent 
after bridging therapy. This clinical benefit of IVT has been pre-
viously reported,13,14 but was not observed in the recent trials.2-5 
Still, especially considering drip-and-ship admissions, IVT is as-
sociated with an improved rate of intracranial recanalization 
before MT, positively influencing clinical outcome.15 Interest-
ingly, in our study, one case of early recanalization after IVT 
was observed whereas no case was noted in the no-IVT group. 
Figure 1. Flowchart. MT, mechanical thrombectomy; IVT, intravenous thrombolysis.
770 Tandem occlusion strokes treated with MT
144 Tandem occlusions related to internal 
carotid artery dissection
526 Tandem occlusions secondary to large 
artery atherosclerosis
94 Patients treated with IVT combined with MT 50 Patients treated with MT alone, without IVT
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No (n=50) Yes (n=94)
Age (yr) 52.0±12.9 51.9±11.0 0.96 1.0
Men 33/50 (66.0) 62/93 (66.7) 0.94 1.4
Medical history
Hypertension 17/45 (37.8) 28/91 (30.8) 0.41 14.8
Diabetes mellitus 2/46 (4.3) 5/91 (5.5) 1.00 5.3
Hypercholesterolemia 3/45 (6.7) 18/91 (19.8) 0.046 39.5
Current smoking 17/44 (38.6) 22/89 (24.7) 0.097 30.3
Current stroke event
NIHSS score* 17 (13–19) 15 (10–20) 0.59 9.5
ASPECTS† 7 (5–8) 7 (6–8) 0.42 14.6
0 0/45 (0.0) 1/86 (1.2)
2 1/45 (2.2) 1/86 (1.2)
3 1/45 (2.2) 2/86 (2.3)
4 6/45 (13.3) 2/86 (2.3)
5 5/45 (11.1) 15/86 (17.4)
6 7/45 (15.6) 10/86 (11.6)
7 9/45 (20.0) 20/86 (23.3)
8 7/45 (15.6) 16/86 (18.6)
9 3/45 (6.7) 10/86 (11.6)
10 6/45 (13.3) 9/86 (10.5)
Initial cerebral imaging 0.67 7.6
MRI 27/48 (56.3) 51/85 (60.0)
CT scan 21/48 (43.8) 34/85 (40.0)
Onset to imaging (min)‡ 127 (81–217) 105 (78–169) 0.19 25.8
Endovascular treatment
Site of intracranial occlusion 0.068 45.7
M1-MCA 28/50 (56.0) 61/94 (64.9)
M2-MCA 11/50 (22.0) 7/94 (7.4)
Intracranial ICA 11/50 (22.0) 25/94 (26.6)
Recanalized occlusion 0/50 (0.0) 1/94 (1.1)
Right-sided infarct 21/46 (45.7) 40/87 (46.0) 0.97 0.7
Onset to groin puncture (min)§ 211 (165–312) 226 (179–290) 0.70 9.5
General anesthesia 18/48 (37.5) 36/93 (38.7) 0.89 2.5
First line intracranial thrombectomy 0.81 15.2
SR 15/48 (31.3) 29/86 (32.6)
CA 23/48 (47.9) 35/86 (40.7)
SR+CA 10/48 (20.8) 22/86 (25.6)
Others 0/48 (0.0) 1/86 (1.2)
Cervical ICA stenting 24/50 (48.0) 45/94 (47.9) 0.99 0.3
Antiplatelet medication during procedure 18/50 (36.0) 37/94 (39.4) 0.69 6.9
Values are presented as mean±standard deviation, number/total number (%), or median (interquartile range).
ASD, absolute standardized difference; NIHSS, National Institutes of Health Stroke Scale; ASPECTS, Alberta Stroke Program Early CT Score; MRI, magnetic res-
onance imaging; CT, computed tomography; MCA, middle cerebral artery; ICA, intracranial carotid artery; SR, stent retriever; CA, contact aspiration.
*1 missing value (1 in intravenous thrombolysis [IVT] group); †13 missing values (IVT group, n=8); ‡38 missing values (IVT group n=23); §30 missing values (IVT 
group, n=21). 
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In our study, for tandem LVOS related to cervical ICA dissec-
tion, bridging therapy seems to improve functional outcome 
compared to MT alone. 
ICH is a feared complication of IVT. In the treatment of tan-
dem occlusion, combining IVT with antiplatelet therapy, espe-
cially in cases of acute stenting, is a questionable approach 
Figure 2. Distribution of 90-day modified Rankin Scale (mRS) scores according to use or not of intravenous thrombolysis (IVT) prior endovascular treatment. 









cOR=2.59; 95% CI, 1.35 to 4.93; P=0.004
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Table 2. Outcomes according to intravenous thrombolysis prior endovascular treatment
Outcome
Intravenous thrombolysis Unadjusted Adjusted††
No (n=50) Yes (n=94) Effect size (95% CI) P Effect size (95% CI) P
Angiographic outcomes
Successful reperfusion 32/50 (64.0) 78/94 (83.0) 2.74 (1.24 to 6.04)* 0.012 2.63 (1.12 to 6.15)* 0.025
First pass effect 14/50 (28.0) 33/94 (35.1) 1.39 (0.65 to 2.95)* 0.39 1.31 (0.87 to 1.42)* 0.33
Groin puncture to reperfusion (min)† 70 (40 to 87)‡ 72 (50 to 89)‡ 0.07 (–0.18 to 0.32)§ 0.56 0.11 (–0.14 to 0.35)§ 0.38
Number of passes 2 (1 to 3)‡ 2 (1 to 3)‡ 1.10 (0.57 to 2.10)∥ 0.78 1.38 (0.70 to 2.68)∥ 0.35
Procedural complications‡‡ 9/50 (18.0)¶ 9/94 (9.6)¶ 0.48 (0.17 to 1.31)* 0.15 0.46 (0.15 to 1.33)* 0.15
Clinical outcomes
90-day favorable outcome 22/46 (47.8) 57/91 (62.6) 1.83 (0.89 to 3.75)* 0.099 1.69 (0.80 to 3.54)* 0.16
90-day excellent outcome 6/46 (13.0) 36/91 (39.6) 4.36 (1.67 to 11.34)* 0.003 4.23 (1.60 to 11.18)* 0.004
90-day mortality 6/46 (13.0) 4/91 (4.4) 0.32 (0.08 to 1.12)* 0.079 0.43 (0.11 to 1.63)* 0.21
24-hour change in NIHSS 0.2 (–2.2 to 2.7)** 3.2 (1.4 to 5.0)** 2.9 (–0.1 to–5.9)†† 0.056 3.6 (0.6 to 4.6)†† 0.018
24-hour change in ASPECTS 1.8 (1.2 to 2.4)∥ 1.1 (0.6 to 1.5)∥ –0.8 (–1.5 to –0.1)** 0.028 –0.8 (–1.6 to –0.03)** 0.040
Day-1 patency of extracranial ICA 14/37 (37.8) 23/58 (39.7) 1.08 (0.46 to 2.52)* 0.86 0.69 (0.26 to 1.79)* 0.44
Any ICH 24/39 (61.5) 29/70 (41.4) 0.44 (0.19 to 0.99)* 0.046 0.41 (0.17 to 0.96)* 0.042
Parenchyma hematoma 7/39 (18.0) 6/70 (8.6) 0.43 (0.13 to 1.38)* 0.16 0.38 (0.11 to 1.29)* 0.14
sICH 7/47 (14.8) 4/94 (4.3) 0.25 (0.07 to 0.92)* 0.036 0.21 (0.05 to 0.80)* 0.021
Successful reperfusion was defined as modified Thrombolysis In Cerebral Infarction (mTICI) 2b/2c/3 at the end of endovascular procedure; first pass effect as 
mTICI 2b/2c/3 after first pass, favorable outcome as 90-day modified Rankin Scale (mRS) 0–2 and excellent outcome as 90-day mRS 0–1.
CI, confidence interval; NIHSS, National Institutes of Health Stroke Scale; ASPECTS, Alberta Stroke Program Early CT Score; ICA, intracranial carotid artery; 
ICH, intracranial hemorrhage; sICH, symptomatic intracranial hemorrhage.
*Odds ratio; †Data among patients who achieved successful reperfusion at end of endovascular procedure; ‡Median (interquartile range); §Mean difference in 
log-transformed value; ∥Common odds ratio; ¶For onset to groin puncture, site of occlusion and cervical ICA stenting for angiographic outcomes and adjusted 
for pre-treatment NIHSS, pre-treatment ASPECTS and onset to groin puncture for clinical outcomes (after handling missing values by multiple imputations); 
**Mean (95% CI) of change from baseline adjusted for baseline values; ††Mean between-group difference in change from baseline (95% CI) adjusted for 
baseline values; ‡‡Detailed complications: non-intravenous thrombolysis (IVT) group (8 ENT, 1 perforation) and IVT group (3 ENT, 5 perforations, 1 extension 
and worsening of the dissection)..
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due to the risk of hemorrhagic complications. Here, the rates of 
stenting and antiplatelet agent use were similar between 
groups and there was no increased risk of ICH in the IVT group. 
Conversely, sICH and any ICH were more frequent in the no-IVT 
group. This finding might be related to a higher proportion of 
patient outside the time window for IVT and/or with larger ini-
tial infarct core on initial imaging in the no-IVT group. This hy-
pothesis is confirmed the sensitivity analysis after exclusion of 
these patients demonstrating no difference in ICH and sICH 
risk between IVT and no-IVT groups. The worse recanalization 
and higher infarct expansion rates in the no-IVT group may 
also explain an increased ICH risk. Indeed, lower recanalization 
rates and poorer day-1 ASPECTS have previously been proven 
to be predictive of higher hemorrhagic risk.6 Also, even if there 
role can be evocated, antiplatelet medications were reported 
safe in the treatment of tandem occlusions, regardless of IVT 
status.16 
One concern with IVT for such indications is the fear of ex-
tension and worsening of the dissection.17,18 This is supported 
by the possible lysis of the arterial wall hematoma allowing 
progression of the dissection and potential ischemic worsening. 
We did not find any evidence supporting this phenomenon or 
its consequences. In particular, the day-1 patency of the cervi-
cal ICA was comparable between groups. 
Our study has several limitations mostly related to its retro-
spective design. The endovascular strategies, stenting protocol, 
and perioperative antiplatelet regimens were not standard-
ized. Decision to administer IVT was left to the discretion of 
local teams. The study was conducted over an extended 
timespan which can constitute a source of bias regarding po-
tential evolution of therapeutic strategies. The absence of core 
lab review of imaging and centralized measurements of in-
farct core, penumbra, and mismatch ratio might also be a lim-
itation. Due to the rarity of tandem occlusion related to dis-
section and the difficulty in forming large subgroups, the sta-
tistical analysis may lack power without no formal sample 
calculation. Due to exploratory nature of the present study, 
comparisons in outcomes were not adjusted for multiplicity 
and we therefore could not excluded false positive findings. 
For all these reasons, the present results should be interpreted 
only as hypothesis generating and should be replicated in fur-
ther larger studies.
Conclusions
IVT before MT for tandem occlusions related to cervical ICA 
dissection seems to be safe and associated with a better 
functional outcome. In the absence of contraindication and 
within the recommended time window, prior IVT may still 
be considered as part of the acute reperfusion therapy for 
tandem occlusions related to cervical ICA dissection.
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Supplementary Table 1. Outcomes according to intravenous thrombolysis prior endovascular treatment after exclusion in the no-IVT group of 15 patients 
outside the time window for IVT and eight with large ischemic core on initial imaging
Outcome
Intravenous thrombolysis Unadjusted
No (n=27) Yes (n=94) Effect size (95% CI) P
Angiographic outcomes
Successful reperfusion 17/27 (63.0) 78/94 (83.0) 2.87 (1.11 to 7.41)* 0.030
First pass effect 7/27 (25.9) 33/94 (35.1) 1.55 (0.59 to 4.04)* 0.37
Groin puncture to reperfusion (min)† 75 (49 to 98)‡ 72 (50 to 89)‡ 0.07 (–0.18 to 0.32)§ 0.56
Number of passes 2 (1 to 4)‡ 2 (1 to 3)‡ 1.16 (0.51 to 2.61)∥ 0.73
Procedural complications 4/27 (14.8) 9/94 (9.6) 0.58 (0.17 to 1.99)* 0.39
Clinical outcomes
90-day favorable outcome 12/24 (50.0) 57/91 (62.6) 1.68 (0.67 to 4.15)* 0.26
90-day excellent outcome 5/24 (20.8) 36/91 (39.6) 2.49 (0.85 to 7.26)* 0.095
90-day mRS (shift analysis) 3 (2 to 4)‡ 2 (1 to 3)‡ 2.08 (0.89 to 4.49)∥ 0.089
90-day mortality 3/24 (12.5)‡ 4/91 (4.4)‡ 0.32 (0.07 to 1.41)* 0.13
24-hour change in NIHSS –0.5 (–4.4 to 3.2)¶ 3.1 (1.3 to 5.0)¶ 3.7 (–0.5 to 8.0)** 0.085
24-hour change in ASPECTS 2.3 (1.5 to 3.2)¶ 1.2 (0.7 to 1.6)¶ –1.2 (–2.1 to –0.2)** 0.013
Day-1 patency of extracranial ICA 8/16 (50.0) 23/58 (39.7) 0.66 (0.21 to 2.00)* 0.46
Any ICH 9/20 (45.0) 29/70 (41.4) 0.86 (0.31 to 2.36)* 0.78
Parenchyma hematoma 3/15 (15.0) 6/70 (8.6) 0.50 (0.12 to 2.02)* 0.356
Values are presented as number/total number (%) unless otherwise as indicated. Successful reperfusion was defined as modified Thrombolysis In Cerebral In-
farction (mTICI) 2b/2c/3 at the end of endovascular procedure; first pass effect as mTICI 2b/2c/3 after first pass, favorable outcome as 90-day mRS 0–2 and 
excellent outcome as 90-day mRS 0–1.
IVT, intravenous thrombolysis; CI, confidence interval; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; ASPECTS, Alberta Stroke 
Program Early CT Score; ICA, intracranial carotid artery; ICH, intracerebral hemorrhage.
*Odds ratio; †Data among patients who achieved successful reperfusion at end of endovascular procedure; ‡Median (interquartile range); §Mean difference in 
log-transformed value; ∥Common odds ratio; ¶Mean (95% CI) of change from baseline adjusted for baseline values; **Mean between-group difference in 
change from baseline (95% CI) adjusted for baseline values.
